Peking University People’s Hospital is conducting a phase II trial evaluating Baricitinib, a Janus kinase inhibitor, in steroid-resistant or relapsed ITP. This single-arm, open-label study is recruiting participants aged 18-70 with primary ITP, a platelet count <30,000/µl for over 6 months and have failed at least one ITP treatment. Participants with secondary ITP, active or previous malignancy, active infection, are pregnant, or experienced a thrombotic event in the previous 24 weeks will be unable to enrol in the study.
China
https://www.clinicaltrials.gov/ct2/show/NCT05446831?recrs=a&cond=Immune+Thrombocytopenia&draw=2
Status: unknown